Drug Profile
Research programme: tankyrase inhibitors - Merck Serono/The Institute of Cancer Research
Latest Information Update: 06 Aug 2023
Price :
$50
*
At a glance
- Originator Merck Serono; The Institute of Cancer Research
- Class Small molecules
- Mechanism of Action Tankyrase inhibitors; Wnt signalling pathway inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 06 Aug 2023 Discontinued - Preclinical for Cancer in Germany (unspecified route)
- 06 Aug 2023 Discontinued - Preclinical for Cancer in United Kingdom (unspecified route)
- 28 Nov 2018 No recent reports of development identified for preclinical development in Cancer in Germany